The Effect of Tresiba® (Insulin Degludec) in Type 2 Diabetes Patients in Real World Clinical Practice in China - Noninterventional, Retrospective Chart Review Study
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CN-TREAT
- Sponsors Novo Nordisk
- 27 Sep 2021 Status changed from recruiting to completed.
- 29 Apr 2021 Planned End Date changed from 30 Apr 2021 to 31 Aug 2021.
- 29 Apr 2021 Planned primary completion date changed from 30 Apr 2021 to 31 Aug 2021.